METTL14 represses osteoclast formation to ameliorate osteoporosis via enhancing GPX4 mRNA stability

Abstract

AbstractExcessive bone resorption by osteoclasts results in the development of multiple bone disorders including osteoporosis. This study aimed to explore the biological function of methyltransferase‐like14 (METTL14) in osteoclast formation, as well as its related mechanisms. Expression levels of METTL14, GPX4 and osteoclast‐related proteins TRAP, NFATc1, c‐Fos were detected by qRT‐PCR and Western blotting. The osteoporosis model was established in mice by bilateral ovariectomy (OVX). Bone histomorphology was determined by micro‐CT and H&E staining. NFATc1 expression in bone tissues was determined by immunohistochemical staining. Proliferation of primary bone marrow macrophages cells (BMMs) was assessed by MTT assay. Osteoclast formation was observed by TRAP staining. The regulatory mechanism was evaluated by RNA methylation quantification assay, MeRIP‐qPCR, dual luciferase reporter assay, and RIP, respectively. METTL14 was down‐regulated in the serum samples of postmenopausal osteoporotic women, which was positively associated with bone mineral density (BMD). Osteoclast formation was promoted in OVX‐treated METTL14+/− mice as compared with wild‐type littermates. Conversely, METTL14 overexpression repressed RANKL‐induced osteoclast differentiation of BMMs. Mechanistically, METTL14‐mediated m6A modification post‐transcriptionally stabilized glutathione peroxidase 4 (GPX4), with the assistance of Hu‐Antigen R (HuR). Finally, GPX4 depletion‐mediated osteoclast formation in BMMs could be counteracted by METTL14 or HuR overexpression. Collectively, METTL14 inhibits osteoclastogenesis and bone resorption via enhancing GPX4 stability through an m6A‐HuR dependent mechanism. Therefore, targeting METTL14 might be a novel promising treatment strategy for osteoporosis.